14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ADAP ranks #19839 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Adaptimmune Therapeutics plc Stock Forecast NASDAQ:ADAP

$2.89 (-2.03%)

Volume: 850k

Closed: Jan 21, 2022

Hollow Logo Score: -7.424

Adaptimmune Therapeutics plc Stock Forecast

$2.89 (-2.03%)

Volume: 850k

Closed: Jan 21, 2022

Score Hollow Logo -7.424

Adaptimmune Therapeutics plc Company Profile

101 Park Drive

Abingdon OX14 4RY

44 12 3543 0000


Industry: Biotechnology

Sector: Healthcare

Adaptimmune Therapeutics plc


Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company’s lead program includes NY-ESO cancer antigen, which is in Phase 1/2 clinical trials for the treatment of patients with solid tumors, as well as hematological cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune Therapeutics plc is also developing MAGE A-10 TCR that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer and other solid tumors; and Alpha Fetoprotein TCR therapeutic candidate that has completed preclinical testing for targeting a peptide associated with hepatocellular carcinoma. It has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program; and strategic alliance with MD Anderson Cancer Center for the development of adoptive T-cell therapies for various cancers. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE